These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 1947314

  • 1. Preliminary results of MR imaging with superparamagnetic iron oxide in pancreatic and retroperitoneal disorders.
    Torres GM, Erquiaga E, Ros PR, Burton SS, Barreda R, Langmo LS, Kennedy SJ.
    Radiographics; 1991 Sep; 11(5):785-91; discussion 792-3. PubMed ID: 1947314
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.
    Grubnic S, Padhani AR, Revell PB, Husband JE.
    AJR Am J Roentgenol; 1999 Jul; 173(1):173-8. PubMed ID: 10397122
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases.
    Haldemann Heusler RC, Wight E, Marincek B.
    J Magn Reson Imaging; 1995 Jul; 5(4):385-91. PubMed ID: 7549199
    [Abstract] [Full Text] [Related]

  • 6. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC, Freeny PC, Nghiem HV, Mack LA, Patten RM, Thomas CR, Elliott S.
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [Abstract] [Full Text] [Related]

  • 7. MRI of pelvic masses: efficacy of the rectal superparamagnetic contrast agent Ferumoxsil.
    Scheidler J, Heuck AF, Meier W, Reiser MF.
    J Magn Reson Imaging; 1997 Dec; 7(6):1027-32. PubMed ID: 9400845
    [Abstract] [Full Text] [Related]

  • 8. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.
    Hudgins PA, Anzai Y, Morris MR, Lucas MA.
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):649-56. PubMed ID: 11950660
    [Abstract] [Full Text] [Related]

  • 9. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits.
    Taupitz M, Wagner S, Hamm B, Binder A, Pfefferer D.
    AJR Am J Roentgenol; 1993 Jul; 161(1):193-200. PubMed ID: 8517301
    [Abstract] [Full Text] [Related]

  • 10. High-resolution T2-weighted abdominal magnetic resonance imaging using respiratory triggering: impact of butylscopolamine on image quality.
    Wagner M, Klessen C, Rief M, Elgeti T, Taupitz M, Hamm B, Asbach P.
    Acta Radiol; 2008 May; 49(4):376-82. PubMed ID: 18415778
    [Abstract] [Full Text] [Related]

  • 11. MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent.
    Maccioni F, Bruni A, Viscido A, Colaiacomo MC, Cocco A, Montesani C, Caprilli R, Marini M.
    Radiology; 2006 Feb; 238(2):517-30. PubMed ID: 16371574
    [Abstract] [Full Text] [Related]

  • 12. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.
    Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB.
    AJNR Am J Neuroradiol; 1994 Jan; 15(1):87-94. PubMed ID: 7511324
    [Abstract] [Full Text] [Related]

  • 13. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma.
    Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, Robinson RA, Amorosa JK, Mammone JF, Outwater EK.
    J Magn Reson Imaging; 1999 Sep; 10(3):468-73. PubMed ID: 10508310
    [Abstract] [Full Text] [Related]

  • 14. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent.
    Pannu HK, Wang KP, Borman TL, Bluemke DA.
    J Magn Reson Imaging; 2000 Dec; 12(6):899-904. PubMed ID: 11105028
    [Abstract] [Full Text] [Related]

  • 15. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging.
    Shamsi K, Balzer T, Saini S, Ros PR, Nelson RC, Carter EC, Tollerfield S, Niendorf HP.
    Radiology; 1998 Feb; 206(2):365-71. PubMed ID: 9457187
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography.
    Bellin MF, Lebleu L, Meric JB.
    Abdom Imaging; 2003 Feb; 28(2):155-63. PubMed ID: 12592461
    [Abstract] [Full Text] [Related]

  • 17. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
    Saksena MA, Saokar A, Harisinghani MG.
    Eur J Radiol; 2006 Jun; 58(3):367-74. PubMed ID: 16472955
    [Abstract] [Full Text] [Related]

  • 18. Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide.
    Small WC, Nelson RC, Bernardino ME.
    Magn Reson Imaging; 1993 Jun; 11(5):645-54. PubMed ID: 8345779
    [Abstract] [Full Text] [Related]

  • 19. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
    Oksendal AN, Jacobsen TF, Gundersen HG, Rinck PA, Rummeny E.
    Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
    [No Abstract] [Full Text] [Related]

  • 20. Oral magnetic particles in MR imaging of the abdomen and pelvis.
    Rinck PA, Smevik O, Nilsen G, Klepp O, Onsrud M, Oksendal A, Børseth A.
    Radiology; 1991 Mar; 178(3):775-9. PubMed ID: 1994417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.